Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR

Omalizumab is a recombinant DNA-derived humanized monoclonal antibody targeting free immunoglobulin E. In the omalizumab phase III studies for chronic rhinosinusitis with nasal polyp (CRSwNP), a clinically relevant reduction of the nasal polyp score (NPS) was observed leading to improved SinoNasal Outcome Test-22 (SNOT-22) (1). In the extension study, sustained or further improvement of symptoms and NPS reduction were observed up to 52 weeks (2). Real-world data is needed to establish effectiveness in uncontrolled severe CRSwNP (3), but so far, data on long-term omalizumab treatment is sparse (4,5).

Authors

Institutions

Publication Details

Journal
Rhinology Journal
Published
2026-02-01
DOI
https://doi.org/10.4193/rhin25.514
Primary Topic
Sinusitis and nasal conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR

Tina Bartosik, V. Hox, Xavier González-Compta, Julia Eckl-Dorna et al.
Rhinology Journal
Sinusitis and nasal conditions
article

Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR

Tina Bartosik, V. Hox, Xavier González-Compta, Julia Eckl-Dorna, Zuzana Diamant, Martin Bruch, M. Burian, Alexandros Andrianakis, Giulia Bettio, Joost de Kinderen, Christina Morgenstern, Gert Mariën, L Pardo Muñoz, P-V Tomazic, K Scheckenbach, C Bachert, A Tu, S Allu, S F Seys, M Wagenmann, S Schneider, M Golet Fors
article en

Abstract

Omalizumab is a recombinant DNA-derived humanized monoclonal antibody targeting free immunoglobulin E. In the omalizumab phase III studies for chronic rhinosinusitis with nasal polyp (CRSwNP), a clinically relevant reduction of the nasal polyp score (NPS) was observed leading to improved SinoNasal Outcome Test-22 (SNOT-22) (1). In the extension study, sustained or further improvement of symptoms and NPS reduction were observed up to 52 weeks (2). Real-world data is needed to establish effectiveness in uncontrolled severe CRSwNP (3), but so far, data on long-term omalizumab treatment is sparse (4,5).

Rhinology JournalVol. 0(0)
Cliniques Universitaires Saint-Luc (BE), University Medical Center Groningen (NL), Sun Yat-sen University (CN), Medical University of Graz (AT), Charles University (CZ), Bellvitge University Hospital (ES), Vienna General Hospital (AT), Statistics Belgium (BE), Institut d'Investigació Biomédica de Bellvitge (ES), Düsseldorf University Hospital (DE), Novartis (India) (IN), Hospital Terrassa (ES), University Hospital Münster (DE), The First Affiliated Hospital, Sun Yat-sen University (CN), Krankenhaus der Elisabethinen (AT), Thomayer University Hospital (CZ), Heinrich Heine University Düsseldorf (DE), Medical University of Vienna (AT), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 51%
Sinusitis and nasal conditions
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.